Oxford BioMedica PLC risk profile
65 Stretched several inputs deteriorating together
Measured 21 October 2026 from OXB's filed statements. Recomputed nightly.
65 (Stretched), driven by Cash conversion at 86, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 69 | Stretched | Volatile | One-year price volatility — 50.6% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -13.9 percentage points |
| Cash conversion | 86 | Acute | Easing | Capital spending against operating cash — 9.39x |
| Leverage and coverage | 86 | Acute | Stable | Net debt to EBITDA — 21.25x |
| Competitive position | 81 | Acute | Stable | Operating-margin gap against peers — -20.1 percentage points |
| Concentration | 74 | Stretched | Stable | Geographic concentration — 7,245 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Oxford BioMedica PLC